Zacks Investment Research highlights Exelixis (EXEL) as a compelling growth stock, citing its Growth Score of A and Zacks Rank #2. Exelixis is projected to achieve EPS growth of 30.4% this year, significantly outpacing the industry average of 19.4%, and boasts a year-over-year cash flow growth of 135.6%. Furthermore, current-year earnings estimates for Exelixis have seen a 13.9% surge over the past month, reinforcing its potential for outperformance.
Exelixis (EXEL) is presented by Zacks Investment Research as a prime candidate for growth-focused investors, distinguished by a Zacks Growth Score of A and a Zacks Rank #2 (Buy). The company's projected earnings per share (EPS) growth for the current year stands at an impressive 30.4%, substantially exceeding the industry average forecast of 19.4%. This earnings momentum is complemented by robust cash flow dynamics; Exelixis reports a year-over-year cash flow growth of 135.6%, a figure that starkly contrasts with the industry's average decline of 4.9%. Furthermore, its annualized cash flow growth rate over the past 3-5 years, at 10.8%, also surpasses the industry's 3.4% average. The positive outlook is further substantiated by recent upward revisions in earnings estimates, with the Zacks Consensus Estimate for Exelixis's current-year earnings having increased by 13.9% over the last month. According to Zacks, this confluence of strong growth metrics and positive estimate revisions positions Exelixis for potential market outperformance, although investors should note the inherent above-average risk and volatility typically associated with growth stocks.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.80
Ticker Sentiment